Visual Performance Of An Extended Depth Of Focus Intraocular Lens In Eyes With Low To Moderate Irregular Astigmatism – An Interims Analysis
Published 2024 - 42nd Congress of the ESCRS
Reference: PP22.01 | Type: Free paper | DOI: 10.82333/hxhv-pg76
Authors: Daniel Schartmüller* 1 , Victor Danzinger 1 , Marcus Lisy 1 , Markus Schranz 1 , Ioanna Dimakopoulou 1 , Claudette Abela-Formanek 1 , Christina Leydolt 1
1Ophthalmology and Optometry,Medical University of Vienna,Vienna,Austria
Purpose
To test monocular and binocular far and intermediate vision in patients with low to moderate irregular astigmatism receiving an enhanced depth of focus (EDOF) intraocular lens (IOL).
Setting
Medical University of Vienna
Methods
Patients with irregular astigmatism exhibiting an anterior root mean square (RMS/a) of 0.3µm/mm2 or higher in the 3.0 mm zone in at least one eye were included in the study. Irregular astigmatism was measured using an anterior segment OCT MS-39 (CSO, Firenze, Italy). All patients received either a monofocal Acrysof Vivity DFT015 or toric DFT215-615 IOL if the total astigmatism was more than 0.75 diopters (D). Monocular and binocular best-corrected distance visual acuity (BCDVA), monocular distance-corrected intermediate visual acuity (DCIVA) at 66cm and monocular distance-corrected near visual acuity (DCNVA) at 40cm were assessed using ETDRS charts at 4 months (4m). Monocular defocus curves were assessed at 4m.
Results
Ten patients including 20 eyes were assessed for the interims analysis. Mean preoperative RMS/a was 0.035±0.007µm/mm2. Monocular BCDVA at 4m for the study eye was -0.03±-0.05 logMAR. Binocular BCDVA was -0.09±0.06 logMAR. Monocular DCIVA was 0.19±0.1 logMAR. Monocular DCNVA was 0.36±0.06 logMAR.
Conclusions
Patients exhibiting low to moderate irregular astigmatism showed very good postoperative monocular and binocular distance visual acuity below 0.0 logMAR. Accordingly, intermediate and near vision showed similar results using an EDOF IOL. Low to moderate irregular astigmatism is not an exclusion criterion for Vivity EDOF IOL implantation.